National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.

Rapid Review

Commenced Completed Outcome
15/12/2011 05/01/2012 Full Pharmacoeconomic Evaluation Recommended

 Pharmacoeconomic Evaluation

Commenced Completed Outcome
26/11/2012  20/03/2013 Reimbursement Not Recommended

The NCPE believe that, at the submitted price, pirfenidone is not cost-effective for the treatment of patients with mild to moderate Idiopathic Pulmonary Fibrosis.

Pirfenidone (Esbriet) Summary

March 2015

The HSE has approved reimbursement following confidential price negotiations.